A1 Journal article – refereed

18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

List of Authors: Karen Juul Mylam, Lale Kostakoglu, Martin Hutchings, Morton Coleman, Dominick Lamonica, Myron S. Czuczman, Louis F. Diehl, Anne L. Nielsen, Paw Jensen, Annika Loft, Helle W. Hendel, Victor Iyer, Sirpa Leppä, Sirkku Jyrkkiö, Harald Holte, Mikael Eriksson, Dorte Gillstrøm, Per B. Hansen, Marko Seppänen, Karin Hjorthaug, Peter de Nully Brown, Lars M. Pedersen

Publisher: Informa UK, Ltd.

Publication year: 2015

Journal: Leukemia and Lymphoma

Journal acronym: Leukemia & Lymphoma

Volume number: 56

Issue number: 7

Number of pages: 8

ISSN: 1042-8194

eISSN: 1029-2403

DOI: http://dx.doi.org/10.3109/10428194.2014.975800

URL: http://informahealthcare.com.ezproxy.utu.fi:2048/doi/pdf/10.3109/10428194.2014.975800


We evaluated the predictive value of interim positon emission tomography (I-PET) after one course of chemoimmunotherapy in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). One hundred and twelve patients with DLBCL were enrolled. All patients had PET/computed tomography (CT) scans performed after one course of chemotherapy (PET-1). I-PET scans were categorized according to International Harmonization Project criteria (IHP), Deauville 5-point scale (D 5PS) with scores 1-3 considered negative (D 5PS > 3) and D 5PS with scores 1-4 considered negative (D 5PS = 5). Ratios of tumor maximum standardized uptake value (SUVmax) to liver SUVmax were also analyzed. We found no difference in progression-free survival (PFS) between PET-negative and PET-positive patients according to IHP and D 5PS > 3. The 2-year PFS using D 5PS = 5 was 50.9% in the PET-positive group and 84.8% in the PET-negative group (p = 0.002). A tumor/liver SUVmax cut-off of 3.1 to distinguish D 5PS scores of 4 and 5 provided the best prognostic value. PET after one course of chemotherapy was not able to safely discriminate PET-positive and PET-negative patients in different prognostic groups.

Last updated on 2021-24-06 at 10:39